Vera Therapeutics VERA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $86.01M+45.0% | $59.31M+5.0% | $56.47M-3.0% | $58.2M+41.0% | $41.28M+23.8% | ||
| $39.12M+12.1% | $34.9M+27.1% | $27.46M+25.1% | $21.95M+37.9% | $15.92M+2.2% | ||
| $125.13M+32.8% | $94.21M+12.2% | $83.93M+4.7% | $80.14M+40.1% | $57.19M+16.9% | ||
| $125.13M+32.8% | $94.21M+12.2% | $83.93M+4.7% | $80.14M+40.1% | $57.19M+16.9% | ||
| -$125.13M-32.8% | -$94.21M-12.2% | -$83.93M-4.7% | -$80.14M-40.1% | -$57.19M-16.9% | ||
| $1.82M-4.3% | $1.9M-2.9% | $1.96M+4.6% | $1.87M+4.6% | $1.79M-4.2% | ||
| $6.36M+15.2% | $5.52M-3.8% | $5.74M-9.2% | $6.32M-8.5% | $6.91M+3.6% | ||
| $4.1M+31.8% | $3.11M-14.5% | $3.64M+0.8% | $3.61M-34.4% | $5.5M+0.2% | ||
| —— | -$74.9M0.0% | -$74.9M0.0% | -$74.9M0.0% | -$74.9M-96.9% | ||
| -$121.03M-32.9% | -$91.1M-13.5% | -$80.29M-4.9% | -$76.53M-48.0% | -$51.69M-19.0% | ||
| -$1.69-21.6% | -$1.39-10.3% | -$1.26-5.0% | -$1.20-48.1% | -$0.81-12.5% | ||
| -$1.69-21.6% | -$1.39-10.3% | -$1.26-5.0% | -$1.20-48.1% | -$0.81-12.5% | ||
| 71.5M+11.3% | 64.2M+0.6% | 63.8M+0.1% | 63.8M+0.2% | 63.7M+15.1% | ||
| 71.5M+11.3% | 64.2M+0.6% | 63.8M+0.1% | 63.8M+0.2% | 63.7M+15.1% | ||
| -$942K— | —— | $354K+379% | -$127K-149% | $261K— | ||
| -$432K+14.1% | -$503K-267% | -$137K+83.6% | -$836K-317% | $386K-44.7% | ||
| -$125.13M-32.8% | -$94.21M-12.2% | -$83.93M-4.7% | -$80.14M-40.1% | -$57.19M-16.9% | ||
| -$124.99M-32.9% | -$94.07M-12.3% | -$83.8M-4.7% | -$80.02M-40.1% | -$57.11M-16.9% | ||
| -$124.99M-32.9% | -$94.07M-12.3% | -$83.8M-4.7% | -$80.02M-40.1% | -$57.11M-16.9% | ||
| -$125.13M-32.8% | -$94.21M-12.2% | -$83.93M-4.7% | -$80.14M-40.1% | -$57.19M-16.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Vera Therapeutics's income statement data come from?
- Every line is extracted from Vera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.